The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema ...
Denmark-headquartered Novo Nordisk, a leading global healthcare company founded in 1923 to drive change to defeat serious chronic diseases built upon our heritage in diabetes, announced headline ...
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to Eli Lilly’s (LLY) tirzepatide. Share price reaction ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Novo Nordisk A/S Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week ...
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback